Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
06
2022
accepted:
19
07
2022
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
20
9
2022
Statut:
epublish
Résumé
In response to the COVID-19 pandemic, COVID-19 vaccines have been developed, and the World Health Oraganization (WHO) has granted emergency use listing to multiple vaccines. Studies of vaccine immunogenicity data from implementing COVID-19 vaccines by national immunization programs in single studies spanning multiple countries and continents are limited but critically needed to answer public health questions on vaccines, such as comparing immune responses to different vaccines and among different populations.
Identifiants
pubmed: 36107966
doi: 10.1371/journal.pone.0273914
pii: PONE-D-22-15998
pmc: PMC9477293
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0273914Subventions
Organisme : FIC NIH HHS
ID : D43 TW011818
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cell Host Microbe. 2021 Dec 8;29(12):1738-1743.e4
pubmed: 34861167
Expert Rev Vaccines. 2010 Apr;9(4):409-29
pubmed: 20370551
Clin Infect Dis. 2022 Mar 23;74(6):1030-1038
pubmed: 34185847
Lancet. 2022 Feb 5;399(10324):530-540
pubmed: 35093205
N Engl J Med. 2021 Mar 11;384(10):905-914
pubmed: 33356051
Lancet Infect Dis. 2022 May;22(5):622-635
pubmed: 34953520
medRxiv. 2021 Sep 28;:
pubmed: 34611671
Diagnostics (Basel). 2021 Jun 25;11(7):
pubmed: 34202195
Ann Intern Med. 2022 Feb;175(2):234-243
pubmed: 34928698
Sci Rep. 2022 Dec 22;12(1):22175
pubmed: 36550362